The global Immunoassay analyzers market size was estimated at USD 7.18 billion in 2024 and is expected to grow at a CAGR of 4.13% from 2025 to 2030. The increasing prevalence of chronic diseases, including both infectious and non-infectious conditions, is a significant driver of market growth for immunoassay analyzers. As the burden of diseases such as cancer and cardiovascular conditions continues to rise, technological advancements and the application of immunoassay analyzers are expanding rapidly. These advancements play a crucial role in early diagnosis, disease monitoring, and treatment planning. The World Health Organization (WHO) reported approximately 20 million new cancer cases in 2022, with a projected increase in diagnoses reaching 53.5 million in the coming years. This surge in chronic illnesses is fueling the demand for innovative immunoassay solutions, leading companies to develop more advanced and effective diagnostic technologies.
The outbreak of the COVID-19 pandemic further emphasized the need for rapid and accurate diagnostic tools. The emergence of the SARS-CoV-2 virus created an urgent demand for accelerated diagnostic methods that could offer both precision and affordability. While RT-PCR tests were widely used for early detection, they were often considered expensive and resource-intensive. This led to the widespread deployment of immunoassay analyzers for detecting antibodies, providing a more cost-effective and efficient alternative. Companies responded swiftly to this demand by launching advanced immunoassay solutions. For instance, Agilent Technologies, Inc. introduced the Agilent Dako SARS-CoV-2 enzyme-linked immunoassay kit, designed to detect SARS-CoV-2 antibodies in human serum or plasma. The pandemic heightened awareness about the capabilities of immunoassay analyzers, accelerating technological developments and market expansion.
The increasing prevalence of chronic diseases has driven continuous advancements in immunoassay technologies. The emergence of new infectious diseases, growing concerns over antibiotic resistance, and the rising demand for personalized medicine have spurred the need for highly sensitive, specific, and rapid immunoassay tests. Various companies are investing in innovative solutions to meet these evolving healthcare needs. Diamond Diagnostics, for example, is committed to enhancing immunoassay diagnostics by manufacturing high-quality, cost-effective consumables and accessories for immunoassay analyzers. Such innovations contribute to the expansion of the market, ensuring that healthcare providers have access to reliable and advanced diagnostic tools.
In addition to technological advancements, strategic collaborations among key industry players are significantly contributing to market growth. Companies are increasingly forming partnerships to strengthen their immunoassay capabilities, support therapeutic advancements, and facilitate clinical adoption. A notable example is the collaboration between Beckman Coulter, Inc. and Fujirebio in July 2023. This partnership aims to enhance immunoassay applications in neurodegenerative disease research, clinical trials, routine diagnostics, and reimbursement processes. By combining expertise and resources, these collaborations are driving innovation and improving the accessibility of advanced diagnostic solutions.
This product will be delivered within 1-3 business days.
The outbreak of the COVID-19 pandemic further emphasized the need for rapid and accurate diagnostic tools. The emergence of the SARS-CoV-2 virus created an urgent demand for accelerated diagnostic methods that could offer both precision and affordability. While RT-PCR tests were widely used for early detection, they were often considered expensive and resource-intensive. This led to the widespread deployment of immunoassay analyzers for detecting antibodies, providing a more cost-effective and efficient alternative. Companies responded swiftly to this demand by launching advanced immunoassay solutions. For instance, Agilent Technologies, Inc. introduced the Agilent Dako SARS-CoV-2 enzyme-linked immunoassay kit, designed to detect SARS-CoV-2 antibodies in human serum or plasma. The pandemic heightened awareness about the capabilities of immunoassay analyzers, accelerating technological developments and market expansion.
The increasing prevalence of chronic diseases has driven continuous advancements in immunoassay technologies. The emergence of new infectious diseases, growing concerns over antibiotic resistance, and the rising demand for personalized medicine have spurred the need for highly sensitive, specific, and rapid immunoassay tests. Various companies are investing in innovative solutions to meet these evolving healthcare needs. Diamond Diagnostics, for example, is committed to enhancing immunoassay diagnostics by manufacturing high-quality, cost-effective consumables and accessories for immunoassay analyzers. Such innovations contribute to the expansion of the market, ensuring that healthcare providers have access to reliable and advanced diagnostic tools.
In addition to technological advancements, strategic collaborations among key industry players are significantly contributing to market growth. Companies are increasingly forming partnerships to strengthen their immunoassay capabilities, support therapeutic advancements, and facilitate clinical adoption. A notable example is the collaboration between Beckman Coulter, Inc. and Fujirebio in July 2023. This partnership aims to enhance immunoassay applications in neurodegenerative disease research, clinical trials, routine diagnostics, and reimbursement processes. By combining expertise and resources, these collaborations are driving innovation and improving the accessibility of advanced diagnostic solutions.
Global Immunoassay Analyzers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, the analyst has segmented the global Immunoassay analyzers market report on the basis of product, application, end use, region:Product Outlook (Revenue, USD Million, 2018 - 2030)
- Chemiluminescence Immunoassays (CLIA)
- Fluorescence Immunoassays (FIA)
- Radioimmunoassay
- Enzyme-Linked Immunoassay
- Consumables and Accessories
Application Outlook (Revenue, USD Million, 2018 - 2030)
- Therapeutic Drug Monitoring
- Oncology
- Cardiology
- Endocrinology
- Infectious Disease Testing
- Autoimmune Disease
- Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals & Clinics
- Diagnostic Laboratories
- Research Institutes
- Regional Outlook (Revenue in USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Immunoassay Analyzers Market Variables, Trends & Scope
Chapter 4. Immunoassay Analyzers Market: Product Estimates & Trend Analysis
Chapter 5. Immunoassay Analyzers Market: Application Estimates & Trend Analysis
Chapter 6. Immunoassay Analyzers Market: End Use Estimates & Trend Analysis
Chapter 7. Immunoassay Analyzers Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Siemens Healthineers AG
- BIOMÉRIEUX
- Abbott
- QuidelOrtho Corporation
- Sysmex Corporation
- BD
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Beckman Coulter, Inc.
- DiaSorin S.p.A.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 150 |
Published | March 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 7.18 Billion |
Forecasted Market Value ( USD | $ 9.15 Billion |
Compound Annual Growth Rate | 4.1% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |